DOI QR코드

DOI QR Code

Association Between the c.3751G>A Genetic Variant of MDR1 and Hepatocellular Carcinoma Risk in a Chinese Han Population

  • Li, Xiao-Fei (Department of Infectious Diseases, The YiWu Central Hospital) ;
  • He, Hua-Bin (Department of Orthopedics, The YiWu Central Hospital) ;
  • Zhu, Yan-Shuang (Department of Infectious Diseases, The YiWu Central Hospital) ;
  • He, Jin-Ke (Department of Infectious Diseases, The YiWu Central Hospital) ;
  • Ye, Wei-Wei (Department of Infectious Diseases, The YiWu Central Hospital) ;
  • Chen, Yong-Xin (Department of Infectious Diseases, The YiWu Central Hospital) ;
  • Lou, Lian-Qing (Department of Infectious Diseases, The YiWu Central Hospital)
  • Published : 2013.09.30

Abstract

The objective of this study was to evaluate the influence of a genetic variant in the multidrug resistance 1 gene (MDR1) on hepatocellular carcinoma (HCC) risk. This case-control study was conducted in a Chinese population of 645 HCC cases and 658 cancer-free controls. The genotype of the c.3751G>A genetic variant in the MDR1 gene was investigated by created restriction site-polymerase chain reaction (CRS-PCR) and DNA sequencing methods. Our data demonstrated significantly differences detected in the allelic and genotypic frequencies between HCC cases and those of cancer-free controls. Association analyses indicated that there were statistically increased risk of HCC in the homozygote comparison (AA versus (vs.) GG: OR=2.22, 95% CI 1.51-3.27, ${\chi}^2$=16.90, P<0.001), dominant model (AA/GA vs. GG: OR=1.25, 95% CI 1.00-1.55, ${\chi}^2$=3.98, P=0.046), recessive model (AA vs. GA/GG: OR=2.14, 95% CI 1.47-3.09, ${\chi}^2$=16.68, P<0.001) and allele comparison (A vs. G: OR=1.33, 95% CI 1.13-1.57, ${\chi}^2$=11.66, P=0.001). The allele-A and genotype-AA may contribute to HCC susceptibility. These preliminary findings suggest that the c.3751G>A genetic variant in the MDR1 gene is potentially related to HCC susceptibility in a Chinese Han population, and might be used as a molecular marker for evaluating HCC susceptibility.

Keywords

Hepatocellular carcinoma;MDR1 gene;genetic variant;susceptibility;molecular biomarker

References

  1. Amarapurkar DN, Patel ND, Kamani PM (2008). Impact of diabetes mellitus on outcome of HCC. Ann Hepatol, 7, 148-51.
  2. Bayram S, Akkiz H, Bekar A, et al (2012). The significance of Exonuclease 1 K589E polymorphism on hepatocellular carcinoma susceptibility in the Turkish population: a casecontrol study. Mol Biol Rep, 39, 5943-51. https://doi.org/10.1007/s11033-011-1406-x
  3. Bosch FX, Ribes J, Diaz M, et al (2004). Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, S5-16. https://doi.org/10.1016/S0016-5085(04)01170-9
  4. Cavaco I, Gil JP, Gil-Berglund E, et al (2003). CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med, 41, 1345-50.
  5. Chen JG, Zhang SW, Chen WQ (2010). Analysis of liver cancer mortality in the national retrospective sampling survey of death causes in China, 2004 - 2005. Zhonghua Yu Fang Yi Xue Za Zhi, 44, 383-9.
  6. Chen XJ, Wang XG, Shen YJ, et al (2011). Correlation of MDR1 single nucleotide polymorphism with prognosis of hepatocellular carcinoma. J Chin Oncol, 17, 209-11.
  7. Gao J (2013). Association of MDR1 gene polymorphisms with the risk of hepatocellular carcinoma in the Chinese Han population. Braz J Med Biol Res, 46, 311-7. https://doi.org/10.1590/1414-431X20132774
  8. Chen YD, Yang F, Feng ST, et al (2009). A case-control study on the association between genetic polymorphisms of MDR1 and hepatic cell cancer susceptibility. Chin Clin Oncol, 14, 1077-81.
  9. El-Serag HB, Rudolph KL (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-76. https://doi.org/10.1053/j.gastro.2007.04.061
  10. Farazi PA, DePinho RA (2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer, 6, 674-87. https://doi.org/10.1038/nrc1934
  11. Gomaa AI, Khan SA, Toledano MB, et al (2008). Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8. https://doi.org/10.3748/wjg.14.4300
  12. Haliassos A, Chomel JC, Tesson L, et al (1989). Modification of enzymatically amplified DNA for the detection of point mutations. Nucleic Acids Res, 17, 3606. https://doi.org/10.1093/nar/17.9.3606
  13. Li Y, Wang J, Jiang F, et al (2012). Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese han population: a case control study. BMC Med Genet, 13, 1.
  14. Llovet JM, Burroughs A, Bruix J (2003). Hepatocellular carcinoma. Lancet, 362, 1907-17. https://doi.org/10.1016/S0140-6736(03)14964-1
  15. Marrero JA, Fontana RJ, Fu S, et al (2005). Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol, 42, 218-24.
  16. Nault JC, Zucman-Rossi J (2011). Genetics of hepatobiliary carcinogenesis. Semin Liver Dis, 31, 173-87. https://doi.org/10.1055/s-0031-1276646
  17. Ning S, Bin C, Na H, et al (2012). Glypican-3, a novel prognostic marker of hepatocellular cancer, is related with postoperative metastasis and recurrence in hepatocellular cancer patients. Mol Biol Rep, 39, 351-7. https://doi.org/10.1007/s11033-011-0745-y
  18. Pechandova K, Buzkova H, Slanar O, et al (2006). Polymorphisms of the MDR1 gene in the Czech population. Folia Biol (Praha), 52, 184-9.
  19. Parikh S, Hyman D (2007). Hepatocellular cancer: a guide for the internist. Am J Med, 120, 194-202. https://doi.org/10.1016/j.amjmed.2006.11.020
  20. Parkin DM, Bray F, Ferlay J, et al (2001). Estimating the world cancer burden: Globocan 2000. Int J Cancer, 94, 153-6. https://doi.org/10.1002/ijc.1440
  21. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
  22. Ren YQ, Han JQ, Cao JB, et al (2012). Association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma in the Chinese population. Asian Pac J Cancer Prev, 13, 5451-4. https://doi.org/10.7314/APJCP.2012.13.11.5451
  23. Schutte K, Bornschein J, Malfertheiner P (2009). Hepatocellular carcinoma--epidemiological trends and risk factors. Dig Dis, 27, 80-92.
  24. Sumbul AT, Akkiz H, Bayram S, et al (2012). p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a casecontrol study. Mol Biol Rep, 39, 1639-47. https://doi.org/10.1007/s11033-011-0903-2
  25. Suriawinata A, Xu R (2004). An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis, 24, 77-88.
  26. Thorgeirsson SS, Grisham JW (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 31, 339-46. https://doi.org/10.1038/ng0802-339
  27. Vander Borght S, Komuta M, Libbrecht L, et al (2008). Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int, 28, 1370-80. https://doi.org/10.1111/j.1478-3231.2008.01889.x
  28. Yu L, Sun L, Jiang YF, et al (2012). Interactions between CYP1A1 polymorphisms and cigarette smoking are associated with the risk of hepatocellular carcinoma: evidence from epidemiological studies. Mol Biol Rep, 39, 6641-46. https://doi.org/10.1007/s11033-012-1469-3
  29. Wang LY, You SL, Lu SN, et al (2003). Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes Control, 14, 241-50. https://doi.org/10.1023/A:1023636619477
  30. Wu L, Xu X, Shen J, et al (2007). MDR1 gene polymorphisms and risk of recurrence in patients with hepatocellular carcinoma after liver transplantation. J Surg Oncol, 96, 62-8. https://doi.org/10.1002/jso.20774
  31. Yang D, Zhou F, Wang X, et al (2013). Association analysis between MDR1 gene polymorphisms and risk of hepatocellular carcinoma in Chinese population. Biomarkers, 18, 236-41. https://doi.org/10.3109/1354750X.2013.773079
  32. Yu X, Xie H, Wei B, et al (2011). Association of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients. PLoS One, 6, e25933. https://doi.org/10.1371/journal.pone.0025933
  33. Yuan ZR, Li J, Li JY, et al (2013). SNPs identification and its correlation analysis with milk somatic cell score in bovine MBL1 gene. Mol Biol Rep, 40, 7-12. https://doi.org/10.1007/s11033-012-1934-z
  34. Yuan ZR, Li JY, Li J, et al (2013). Effects of DGAT1 gene on meat and carcass fatness quality in Chinese commercial cattle. Mol Biol Rep, 40, 1947-54. https://doi.org/10.1007/s11033-012-2251-2
  35. Yuan ZR, Li JY, Li J, et al (2012). Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle. Gene, 505, 190-4. https://doi.org/10.1016/j.gene.2012.05.010
  36. Yuen MF, Hou JL, Chutaputti A (2009). Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol, 24, 346-53. https://doi.org/10.1111/j.1440-1746.2009.05784.x
  37. Zeng X, Liu S, Yu H, et al (2012). DNA repair capacity, DNAstrand break repair gene polymorphisms, and the incidence of hepatocellular carcinoma in southwestern Guangxi of China. DNA Cell Biol, 31, 1384-91. https://doi.org/10.1089/dna.2012.1646
  38. Zhang LS, Liang WB, Gao LB, et al (2012). Association between pri-miR-218 polymorphism and risk of hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol, 31, 761-5. https://doi.org/10.1089/dna.2011.1326
  39. Zhao CJ, Li N, Deng XM (2003). The establishment of method for identifying SNP genotype by CRS-PCR. Yi Chuan, 25, 327-9.

Cited by

  1. Genetic polymorphisms of the multidrug resistance 1 gene MDR1 and the risk of hepatocellular carcinoma vol.36, pp.9, 2015, https://doi.org/10.1007/s13277-015-3407-1